[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"pd-1-antibody\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:pd-1-antibody":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,47,74],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100643728","phase-2-egfr-tkis-plus-pd-1-in-egfr-mutant-advanced-nsclc-100643728",false,"NCT07637448","EGFR-TKIs Plus PD-1 in EGFR-Mutant Advanced NSCLC","A Clinical Study Evaluating the Preliminary Antitumor Activity and Safety of EGFR-TKIs Combined With PD-1 Monoclonal Antibody as First-Line Therapy in Patients With EGFR-Mutant Advanced Non-Small Cell Lung Cancer","Inclusion Criteria:\n\n1. Patients with histologically or cytologically confirmed, previously untreated EGFR-mutant (19del\u002FL858R) locally advanced or metastatic (stage IIIB\u002FIIIC or IV) non-small cell lung cancer (NSCLC), according to the 9th edition of the TNM staging system for lung cancer jointly issued by the International Association for the Study of Lung Cancer (IASLC) and the American Joint Committee on Cancer (AJCC);\n2. Male or female patients aged ≥ 18 years;\n3. Patients who are willing to receive third-generation EGFR-TKI targeted therapy, followed by maintenance therapy with a PD-1 antibody during the stable phase of the disease (defined as no further tumor shrinkage for at least two consecutive assessments based on RECIST v1.1 criteria);\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;\n5. At least one measurable or non-measurable but evaluable lesion according to RECIST version 1.1;\n6. Adequate organ function;\n7. Female or male patients of childbearing potential must agree to use highly effective contraceptive measures throughout the study period;\n8. Willing and able to comply with scheduled visits, treatment plans, laboratory tests, and other study requirements as specified in the visit schedule.\n\nExclusion Criteria:\n\n1. Patients who are ineligible for standard anti-tumor therapy according to routine clinical practice;\n2. Prior treatment with anti-PD-1\u002FPD-L1 immunotherapy;\n3. Concurrent enrollment in another clinical study;\n4. Known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation;\n5. Receipt of systemic corticosteroids or other immunosuppressive therapy within 2 weeks prior to the first dose of study drug;\n6. Receipt of any live vaccine within 4 weeks prior to the first dose of study drug, or planned receipt of live vaccine during the study period;\n7. Presence of brainstem, leptomeningeal, spinal cord metastasis, or spinal cord compression;\n8. Presence of uncontrolled concomitant diseases, including but not limited to decompensated cirrhosis, nephrotic syndrome, uncontrolled metabolic disorders, etc.;\n9. History of severe gastrointestinal ulcer, gastrointestinal perforation, fistula or obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding within 6 months prior to the first dose, or other gastrointestinal diseases that, in the investigator's opinion, may predispose to bleeding or perforation;\n10. Presence of severe uncontrolled cardiovascular disease;\n11. Interstitial lung disease (ILD) (including pulmonary fibrosis or radiation pneumonitis) requiring corticosteroid therapy, or current ILD\u002Fnon-infectious pneumonitis;\n12. Concomitant pulmonary disease resulting in clinically severe impairment of respiratory function;\n13. Chronic autoimmune disease or inflammatory disease requiring systemic therapy or receiving systemic therapy within 2 years prior to the first dose;\n14. Active or history of documented inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis, or chronic diarrhea), intestinal obstruction, or extensive bowel resection;\n15. Diagnosis of Gilbert's syndrome;\n16. Severe infection within 4 weeks prior to the first dose, including but not limited to complications requiring hospitalization, sepsis, or severe pneumonia;\n17. Known active pulmonary tuberculosis;\n18. Known active syphilis infection;\n19. Known history of immunodeficiency, or positive test for human immunodeficiency virus (HIV) antibody;\n20. Presence of active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection;\n21. Known allergy to any component of any study drug, history of severe allergic reactions (e.g., anaphylactic shock), history of severe hypersensitivity to other monoclonal antibodies or recombinant protein-based substances, or history of severe infusion reactions;\n22. Women who are pregnant, breastfeeding, or planning to become pregnant or breastfeed during the study period;\n23. Any disease, medical condition, organ system dysfunction, or social circumstance (including but not limited to psychiatric illness, substance\u002Falcohol abuse, history of drug abuse, etc.) that, in the investigator's opinion, may interfere with the subject's ability to provide informed consent, adversely affect the subject's cooperation and participation in the study, or confound the interpretation of study results.","ALL","18 Years",{"count":19,"type":20},32,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study is an open-label, multicenter, single-arm clinical study.",[26,27,28],"Lung Cancer Non-Small Cell Cancer (NSCLC)","EGFR Activating Mutation","PD-1 Antibody",[30,31,32,33],"Non-Small Cell Cancer (NSCLC)","EGFR-Mutant","EGFR-TKIs","PD-1 Monoclonal Antibody","RECRUITING","2026-06-04",{"date":37,"type":38},"2026-06-09","ACTUAL",{"date":40,"type":38},"2026-05-21",{"date":42,"type":20},"2030-03-01",{"name":44,"class":45},"Nanfang Hospital, Southern Medical University","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":55,"minAge":17,"maxAge":56,"enrollmentInfo":57,"targetDuration":4,"studyType":21,"phases":59,"briefSummary":60,"conditions":61,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":46},"100481842","phase-2-neoadjuvant-chemotherapy-combined-with-pd-1--radical-radiotherapy-in-locally-advanced-cervical-cancer-100481842","NCT05554276","Neoadjuvant Chemotherapy Combined With PD-1 + Radical Radiotherapy in Locally Advanced Cervical Cancer","Neoadjuvant Chemotherapy Combined With PD-1 Antibody + Radical Radiotherapy in Unresectable Locally Advanced Cervical Cancer Patients","PD-1","Inclusion Criteria:\n\n* Patients who were pathologically diagnosed with cervical squamous cell carcinoma and were assessed as unresectable.\n\nExclusion Criteria:\n\n* Any active or present autoimmune disease (eg, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism)","FEMALE","70 Years",{"count":58,"type":20},36,[23],"Based on various external factors and differences in the basic characteristics of patients, in my country, it is not clear whether concurrent chemoradiotherapy can achieve optimal therapeutic effect in patients with pathologically diagnosed stage IIB or above locally advanced cervical cancer. Under the limitations of radiotherapy and surgery conditions in the region, some patients will try neoadjuvant chemotherapy combined with PD-1 antibody therapy before standard radiotherapy, hoping to reduce cancer focus and reduce infiltration. Thereby reducing the scope of radiotherapy, better ensure the efficacy of late radiotherapy and chemotherapy and reduce the side effects of radiotherapy. Judging from the review of such patients, neoadjuvant chemotherapy combined with PD-1 antibody therapy + radical radiotherapy seems to have certain efficacy and tolerance in the near future as expected. No statistical analysis has been done on the long-term survival of patients. This topic intends to treat inoperable locally advanced cervical cancer patients with neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy, and explore the treatment-related toxic and side effects and efficacy of neoadjuvant chemotherapy combined with PD-1 antibody + radical radiotherapy. It is hoped that through this study, it will provide a reference for the comprehensive treatment of inoperable locally advanced cervical cancer that has been pathologically diagnosed in the future.",[62,28,63,64],"Neoadjuvant Chemotherapy","Radiotherapy","Cervical Cancer","2024-07-24",{"date":67,"type":38},"2024-07-25",{"date":69,"type":38},"2023-08-01",{"date":71,"type":20},"2025-12-31",{"name":73,"class":45},"Shanghai Jiao Tong University Affiliated Sixth People's Hospital",{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":21,"phases":84,"briefSummary":86,"conditions":87,"keywords":4,"overallStatus":91,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":96,"leadSponsor":98,"locationsCount":46},"100498857","phase-3-l-dep-regimen-combined-with-pd-1-antibody-as-induction-therapy-for-epstein-barr-virus-positive-la-hlh-100498857","NCT05775705","L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH","The Efficacy and Safety of L-DEP Regimen Combined With PD-1 Antibody an Induction Therapy for Epstein-Barr Virus (EBV)-Positive Lymphoma-associated Hemophagocytic Lymphohistiocytosis","Inclusion Criteria:\n\n* Diagnosed as lymphoma-Hemophagocytic Lymphohistiocytosis.\n* EBV-DNA in peripheral blood \\> 1000 copies\u002Fml or EBER detected in tissue specimens.\n* Age 18\\~65，gender is not limited.\n* Estimated survival time ≥ 1 month.\n* Cardiac ultrasound LVEF≥50%; No Active bleeding of the internal organs(digestive tract, lung, brain, etc.); If the patient has dyspnea, oxygenation index \\>250.\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Heart function above grade II (NYHA).\n* Severe myocardial injury：TNT、TNI、CK-MB \\> 3 ULN.\n* Accumulated dose of doxorubicin above 400mg\u002Fm2 、epirubicin above 750mg\u002Fm2、pirarubicin above 800mg\u002Fm2 or the patients treated with anthracycline induced cardiovascular disease.\n* Pregnancy or lactating Women.\n* Allergic to pegylated liposomal doxorubicin，etoposide，or PD-1 antibody.\n* Thyroid dysfunction.\n* HIV antibody positivity.\n* Acute or chronic active hepatitis B (HBsAg positivity, HBV DNA negative acceptable), acute or chronic active hepatitis C (HCV antibody negatively acceptable; HCV antibody positivity, HCV RNA negative acceptable).\n* Participate in other clinical research at the same time.\n* The researchers considered that patients are not suitable for the study.","65 Years",{"count":83,"type":20},25,[85],"PHASE3","The efficacy and safety of L-DEP (PEG-aspargase, liposomal doxorubicin, etoposide, and methylprednisolone) regimen combined with PD-1 Antibody an induction therapy for Epstein-Barr virus (EBV)-positive lymphoma-associated hemophagocytic lymphohistiocytosis.",[28,88,89,90],"Hemophagocytic Lymphohistiocytosis","Epstein-Barr Virus","Lymphoma","NOT_YET_RECRUITING","2023-03-08",{"date":94,"type":38},"2023-03-20",{"date":69,"type":20},{"date":97,"type":20},"2026-10-01",{"name":99,"class":45},"Beijing Friendship Hospital"]